Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)

Inclusion Criteria: * Patients aged 75 years or older * ECOG ≤2 * histologically proven unresectable metastatic colorectal adenocarcinoma * Measurable lesion according to RECIST criteria * Absence of prior chemotherapy for metastatic disease. Adjuvant chemotherapy following resection of the primary tumor is authorized if completed more than 6 months previously * Patients treated with anticoagulants (coumadin, warfarin) can be included if close surveillance of the INR can be ensured. A change to low-molecular-weight heparin is preferable as long as the indications are respected * Completed geriatric self-questionnaire * Completed "Team" geriatric questionnaire (including Spitzer QoL Index) * Written informed consent Exclusion Criteria: * Estimated life expectancy \< 3 months * Non-resolved intestinal occlusion or sub-occlusion * Cerebral metastasis * Other evolutive malignant tumor (non-stabilized cancer for less than 2 years) * Evolutive gastroduodenal ulcer, wound or bone fracture * Active heart disease: uncontrolled hypertension, myocardial infarction In the previous 6 months, angina, non-compensated congestive heart failure * Major surgery, except for biopsy, or irradiation in the 4 weeks preceding the start of treatment * Polynuclear neutrophils \<1500/mm3, platelets \<100 000/mm3 or 24-h proteinuria \> 1g * History of arterial thromboembolic event (cerebrovascular accident, transient ischemic attack, subarachnoid hemorrhage) in the 12 months preceding the first dose of bevacizumab * History of distal or visceral ischemia ≥ grade 2 in the 12 months preceding the first dose of bevacizumab * History of life-threatening pulmonary embolism in the 6 months preceding the first dose of bevacizumab * Impossibility to ensure regular follow-up